Business context and reporting period
Solid Biosciences Inc. filed this Form 10-K for the fiscal year ended December 31, 2021. The clinical-stage biotechnology company is developing gene therapies for Duchenne muscular dystrophy (DMD), principally SGT-001 and preclinical candidate SGT-003. It has no approved products and has never generated product-sales revenue. Financial amounts below are in U.S. dollars.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Collaboration revenue | $13.6 million | None |
| Product revenue | None | None |
| Research and development expense | $58.7 million | $64.9 million |
| General and administrative expense | $27.1 million | $21.6 million |
| Total operating expenses | $85.9 million | $88.4 million |
| Net loss | $72.2 million | $88.3 million |
| Net loss per share, basic and diluted | $0.68 | $1.70 |
| Cash used in operating activities | $77.8 million | $56.6 million |
| Cash, cash equivalents and available-for-sale securities at year-end | $207.8 million | $154.7 million in cash and cash equivalents; no available-for-sale securities |
| Debt outstanding | None | Not specified in the cited comparative disclosure |
As a pre-commercial development company, the filing does not present a meaningful product gross margin. The company reported an accumulated deficit of $476.8 million at December 31, 2021. Year-end total assets were $232.4 million, total liabilities $24.2 million, and stockholders’ equity $208.2 million. The company reported no income-tax benefit for 2021 because realization of tax benefits was uncertain.
Material changes versus the prior comparable period
- Net loss narrowed by $16.1 million, or 18%, to $72.2 million. The year included $13.6 million of Ultragenyx collaboration revenue, compared with none in 2020.
- R&D expense fell $6.1 million, primarily because SGT-001 costs declined $6.7 million and SGT-003/other program costs declined $2.2 million; higher unallocated personnel costs partly offset those reductions.
- G&A expense increased $5.6 million, mainly from personnel and consulting costs. There were no restructuring charges in 2021, compared with $1.9 million in 2020.
- Operating cash use increased $21.2 million. The company attributed working-capital effects in part to a $12.6 million decrease in deferred revenue as collaboration services were performed.
- Cash and cash equivalents declined to $119.1 million, while the company held $88.6 million of available-for-sale securities at year-end. Cash flow from investing activities was negative $91.1 million, largely reflecting net purchases of securities.
Outlook, management commentary, risks and unusual items
- Liquidity: Management said year-end cash, cash equivalents and securities of $207.8 million were expected to fund operating expenses and capital requirements into the third quarter of 2023. The estimate depends on assumptions that may prove incorrect; the company expects to need additional funding thereafter and reported no committed external funding source.
- SGT-001: Nine patients had been dosed in the Phase I/II IGNITE DMD trial by the filing date. Patient 8 experienced a drug-related serious systemic inflammatory response in April 2021, which resolved. The FDA had lifted the trial’s 2019 clinical hold in October 2020; the company strengthened risk-mitigation measures before dosing Patient 9 in November 2021. The filing reports complement activation in all nine patients and three resolved serious adverse events. Small-sample interim results are not proof of efficacy.
- SGT-003: The company planned IND-enabling studies in 2022 and an IND submission in early 2023. These are forward-looking targets, not completed milestones.
- Collaboration: Ultragenyx reimburses certain development costs and may owe development, regulatory and sales milestones and royalties. The company recognized $13.6 million of collaboration revenue in 2021 and had $8.1 million of related deferred revenue at year-end. The collaboration provides potential future economics but does not assure milestone or royalty receipts.
- Financing and dilution: A March 2021 public offering raised approximately $134.9 million net and issued 25 million shares. The company had 110.3 million common shares outstanding at year-end, plus 2.2 million pre-funded warrants outstanding.
- Facilities: A new Charlestown, Massachusetts lease is expected to commence in 2022, with an approximately ten-year initial term. The filing reports substantial construction activity and a $10.2 million construction allowance; the new facility adds future occupancy and operating commitments.
- Principal risks: Continued losses and financing needs; clinical safety, efficacy and regulatory uncertainty; manufacturing capacity, quality and third-party dependence; competition; intellectual-property and licensing exposure; and possible clinical or operational disruption from COVID-19. The company cautions that interim clinical data may change as follow-up and verification continue.
The financial statements received an unqualified audit opinion. Management reported disclosure controls and internal control over financial reporting effective as of year-end; the auditor did not provide an attestation on internal control.
Important facts for investors to verify
- Whether the company’s stated runway into Q3 2023 remained achievable under its spending plans and clinical-development assumptions.
- Updated IGNITE DMD safety, biomarker and functional results, including the significance of serious adverse events and the strengthened risk-management protocol.
- Whether SGT-003 met its IND-enabling and planned IND-submission milestones, and the cash required to advance it.
- Ultragenyx development progress, cost reimbursements, remaining deferred revenue, and any milestone, royalty or option-related developments.
- Manufacturing reproducibility, supply capacity and the costs and commitments associated with the new facility.
- Potential share dilution from future financing, equity compensation and outstanding securities.